Fig. 3From: Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in SpainPlane of incremental costs (£) vs. incremental QALYs and Cost-effectiveness acceptability curve: Certolizumab pegol + MTX vs MTX; Certolizumab pegol + MTX vs Adalimumab (every 2 weeks) + MTX and Certolizumab pegol + MTX vs Adalimumab (weekly) + MTXBack to article page